Research programme: CNS disorders therapeutics - Argenta/Lundbeck

Drug Profile

Research programme: CNS disorders therapeutics - Argenta/Lundbeck

Alternative Names: AA 21279; Lu AA21279; NK3 receptor antagonists - Lundbeck

Latest Information Update: 10 Apr 2014

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Developer Argenta; Lundbeck A/S
  • Class Acetic acids; Small molecules
  • Mechanism of Action Glycine reuptake inhibitors; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Schizophrenia

Most Recent Events

  • 10 Apr 2014 Discontinued - Preclinical for Schizophrenia in Europe (unspecified route)
  • 10 Apr 2014 Discontinued - Preclinical for CNS disorders in Europe (unspecified route)
  • 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top